Greywolf Therapeutics
Novel antigen modulation technology to guide the immune system
Greywolf Therapeutics is developing next-generation immunotherapies that restore the body’s ‘immune signals’, revealing diseases to the body’s defences.
The company is conducting clinical trials in oncology and autoimmune disorders and has an earlier stage virology program.
Sector
Life Sciences
Stage
- Series B+